Cardiac function of long-responders to dual anti-HER2 antibodies amongst patients with HER2 positive advanced breast cancer

被引：0
|
作者：
Bao, Kelvin K. H. [1 ]
Chan, Jeffrey C. H. [1 ]
Sutanto, Leone [1 ]
Chan, Jocelyn G. [1 ]
Cheung, Ka Man [1 ]
Yiu, Harry H. Y. [1 ]
机构：
[1] Queen Elizabeth Hosp, Dept Clin Oncol, Hong Kong, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1043
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Real-world impact of dual anti-HER2 antibodies on cardiac function in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer
    Bao, Kelvin K. H.
    Chan, Jeffrey C. H.
    Chan, Jocelyn G.
    Sutanto, Leone
    Cheung, Ka Man
    Yiu, Harry H. Y.
    BREAST, 2024, 73
  • [42] Pathologic complete response to neoadjuvant anti-HER2 therapy is associated with HER2 immunohistochemistry score in HER2-positive early breast cancer
    Chen, Hai-Long
    Chen, Qiang
    Deng, Yong-Chuan
    MEDICINE, 2021, 100 (44)
  • [43] Poziotinib treatment in patients with HER2-positive advanced breast cancer who have received prior anti-HER2 regimens
    Azadeh Nasrazadani
    Juan Luis Gomez Marti
    Kate Lathrop
    Alvaro Restrepo
    Szu-Yun Leu
    Gajanan Bhat
    Adam Brufsky
    Breast Cancer Research and Treatment, 2024, 205 : 29 - 37
  • [44] Poziotinib treatment in patients with HER2-positive advanced breast cancer who have received prior anti-HER2 regimens
    Nasrazadani, Azadeh
    Marti, Juan Luis Gomez
    Lathrop, Kate
    Restrepo, Alvaro
    Leu, Szu-Yun
    Bhat, Gajanan
    Brufsky, Adam
    BREAST CANCER RESEARCH AND TREATMENT, 2024, 205 (01) : 29 - 37
  • [45] Anti-HER2 Th1 Response is Superior to Breast MRI in Assessing Response to Neoadjuvant Chemotherapy in Patients with HER2 Positive Breast Cancer
    De La Cruz, L. M.
    McDonald, E.
    Mick, R.
    Datta, J.
    Geha, R.
    Xu, S.
    Czerniecki, B. J.
    ANNALS OF SURGICAL ONCOLOGY, 2016, 23 : S14 - S15
  • [46] Utilization of anti-HER2 regimens among HER2-positive metastatic breast cancer patients.
    Mehta, Sandhya
    Song, Jinlin
    Pavilack, Melissa
    Xie, Jipan
    Nie, Xiaoyu
    Vembusubramanian, Mohini
    Kwong, Jackie
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (29)
  • [47] Dual anti-HER2 treatment of patients with HER2-positive metastatic colorectal cancer: The HERACLES trial (HER2 Amplification for Colo-rectaL Cancer Enhanced Stratification)
    Marsoni, Silvia
    Bertotti, Andrea
    Sartore-Bianchi, Andrea
    Leone, Francesco
    Lonardi, Sara
    Ciardiello, Fortunato
    Pinto, Carmine
    Aglietta, Massimo
    Zagonel, Vittorina
    Gambacorta, Marcello
    Grigioni, Walter Franco
    Rugge, Massimo
    Risio, Mauro
    Martino, Cosimo
    Valtorta, Emanuele
    Bardelli, Alberto
    Trusolino, Livio
    Comoglio, Paolo M.
    Siena, Salvatore
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [48] Determining the Factors Predicting the Response to Anti-HER2 Therapy in HER2-Positive Breast Cancer Patients
    You, Ji Young
    Park, Kyoung Hwa
    Lee, Eun Sook
    Kwon, Youngmee
    Kim, Kyoung Tae
    Nam, Seungyoon
    Kim, Dong Hee
    Bae, Jeoung Won
    CANCER CONTROL, 2023, 30
  • [49] Determining the Factors Predicting the Response to Anti-HER2 Therapy in HER2-Positive Breast Cancer Patients
    You, Ji Young
    Park, Kyoung Hwa
    Lee, Eun Sook
    Kwon, Youngmee
    Kim, Kyoung Tae
    Nam, Seungyoon
    Kim, Dong Hee
    Bae, Jeoung Won
    CANCER CONTROL, 2022, 29
  • [50] Triple blockade of HER2 by a cocktail of anti-HER2 scFv antibodies induces high antiproliferative effects in breast cancer cells
    Nejatollahi, Foroogh
    Jaberipour, Mansooreh
    Asgharpour, Mahdi
    TUMOR BIOLOGY, 2014, 35 (08) : 7887 - 7895
12345